Literature DB >> 29905361

Treatment of osteoarthritis with collagen-based scaffold: A porcine animal model with xenograft mesenchymal stem cells.

Wo Jan Tseng1, Shu-Wei Huang2, Chih-Hsiang Fang2, Lih-Tao Hsu3, Chih-Yu Chen4, Hsin-Hsin Shen3, Jenny Zwei-Chieng Chang5, Jui-Sheng Sun6, Feng-Huei Lin7.   

Abstract

OBJECTIVE: With the goal to explore a new approach to treat the early degenerative lesions of hyaline cartilage, we implanted in a porcine OA model a collagen-based scaffold containing chondroprogenitor cells derived from human bone marrow mesenchymal stem cells (hBM-MSCs). EXPERIMENTAL
DESIGN: Porcine knee joints were subjected to anterior cruciate ligament (ACL) transection to surgically induce OA. After 4 months, the time necessary for the development of cartilage surface damage, animals were treated either with trephination bone plug wrapped with the chondroprogenic hBM-MSCs-embedded collagen scaffold or microfractures alone. Histological and histomorphometric evaluations were performed at 5 months after surgery.
RESULTS: All animals subjected to ACL transection showed osteoarthritic changes including mild lateral femoral condyle or moderate medial femoral condyle ulcerations. After 14 days' chondrogenic induction, hBM-MSCs seeded onto the scaffold showed expression of chondroprogenitor markers such as SOX9 and COMP. At 5 months after the implantation, significant differences in the quality of the regenerated tissue were found between the hBM-MSCs-embedded scaffold group and the control group. Newly generated tissue was only observed at the site of implantation with the hBM-MSCs-embedded scaffolds. Furthermore, histological examination of the generated tissue revealed evidence of cartilage-like tissue with lacuna formation. In contrast, fibrous layers or fissures were formed on the surface of the control knee joint.
CONCLUSIONS: This study shows that xenogenic hBM-MSC derived chondroprogenitor scaffolds can generate new cartilage tissue in porcine articular cartilage and have the potential as a useful treatment option for osteoarthritis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29905361     DOI: 10.14670/HH-18-013

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  4 in total

Review 1.  Stem cell therapy in pain medicine.

Authors:  Yong Hee Han; Kyung Hoon Kim; Salahadin Abdi; Tae Kyun Kim
Journal:  Korean J Pain       Date:  2019-10-01

Review 2.  Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders.

Authors:  Alexander Markov; Lakshmi Thangavelu; Surendar Aravindhan; Angelina Olegovna Zekiy; Mostafa Jarahian; Max Stanley Chartrand; Yashwant Pathak; Faroogh Marofi; Somayeh Shamlou; Ali Hassanzadeh
Journal:  Stem Cell Res Ther       Date:  2021-03-18       Impact factor: 6.832

Review 3.  Updates on mesenchymal stem cell therapies for articular cartilage regeneration in large animal models.

Authors:  Timothy P Liu; Pin Ha; Crystal Y Xiao; Sang Yub Kim; Andrew R Jensen; Jeremiah Easley; Qingqiang Yao; Xinli Zhang
Journal:  Front Cell Dev Biol       Date:  2022-09-06

Review 4.  The use of large animals to facilitate the process of MSC going from laboratory to patient-'bench to bedside'.

Authors:  W E Hotham; F M D Henson
Journal:  Cell Biol Toxicol       Date:  2020-03-23       Impact factor: 6.691

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.